Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial.
Naomi KiyotaMakato TaharaJunki MizusawaTakeshi KodairaHirofumi FujiiTomoko YamazakiHiroki MitaniShigemichi IwaeYasushi FujimotoYusuke OnozawaNobuhiro HanaiTakenori OgawaHiroki HaraNobuya MondenEiji ShimuraShujiro MinamiTakashi FujiiKaoru TanakaAkihiro HommaSeiichi YoshimotoNobuhiko OridateKoichi OmoriTsutomu UedaKenji OkamiIchiro OtaKiyoto ShigaMasashi SugasawaTakahiro AsakageYuki SaitoShigeyuki MuronoYasumasa NishimuraKenichi NakamuraRyuichi Hayashinull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Chemoradiotherapy with weekly cisplatin is noninferior to 3-weekly cisplatin for patients with postoperative high-risk LA-SCCHN. These findings suggest that chemoradiotherapy with weekly cisplatin can be a possible treatment option for these patients.